ArticleEuropean urology open science2026
Mapping of QLQ-C30 and QLQ-PR25 Scores to EQ-5D-5L Utility Values for Patients with Prostate Cancer Receiving Novel Androgen Receptor Signaling Inhibitors.
Article in European urology open science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cost-effectiveness analysis of neoadjuvant docetaxel plus androgen deprivation therapy before radical prostatectomy in high-risk localized prostate cancer.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: Disease-specific questionnaires provide detailed health insights and are increasingly used in mapping studies to estimate utility values. Given the limited mapping studies in prostate cancer, our aim was to develop mapping algorithms to convert scores from disease-specific questionnaires to EQ-5D utility values for patients receiving novel androgen receptor signaling inhibitors (ARSIs). Methods: This cross-sectional study enrolled prostate cancer patients in Taiwan. Health-related quality of life was assessed using the EQ-5D-5L, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30-item (QLQ-C30), and QLQ-Prostate Cancer 25-item (QLQ-PR25) instruments. Mapping algorithms were developed using ordinary least squares (OLS) and Tobit regression. Model performance was evaluated using the mean absolute error, root mean square error, Akaike information criterion, and Bayesian information criterion. Key findings and limitations: A total of 100 patients were included. The mean EQ-5D index score was 0.71 (standard deviation 0.41), and the mean QLQ-C30 global health status score was 70 (standard deviation 21). Patients using an ARSI for ≥2 yr tended to report lower EQ-5D-5L index scores, global health status, and physical and social functioning, along with higher levels of fatigue, pain, and hormonal treatment-related symptoms. OLS and Tobit models demonstrated good predictive performance. However, given the small sample size, the results remain exploratory and are not intended for direct clinical use. Conclusions and clinical implications: This study provides real-world evidence on the HRQoL of Asian patients with prostate cancer on ARSI therapy. The results demonstrate that QLQ-C30 data can be effectively mapped to EQ-5D-5L utility values. These findings fill a gap in knowledge left by clinical trials. Patient summary: We tested whether quality of life scores reported by patients with prostate cancer who were taking a specific type of hormone therapy could be converted to values that are used in economic analyses. The results show that our mapping method can efficiently convert scores from the QLQ-C30 patient questionnaire to economic utility scores.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.